Page 70 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 70
THURSDAY, APRIL 23, 2015
Parallel Session: Fatty liver disease: Clinical (Cont.) Strauss 3
ABSTRACT DISTINCT FECAL AND PLASMA BILE ACID
O044 METABOLOME OF MICROBIAL ORIGIN
17:00 - 17:15 CHARACTERIZES HUMAN NONALCOHOLIC FATTY
LIVER DISEASE (NAFLD)
SCIENTIFIC PROGRAMME Puneet Puri, The United States
ABSTRACT BIOACTIVE LIPIDS IN THE HUMAN LIVER IN ‘COMMON
O045 NAFLD’ AND ‘PNPLA3 NAFLD’
17:15 - 17:30 Panu Luukkonen, Finland
ABSTRACT SHORT-TERM VITAMIN D SUPPLEMENTATION
O046 IMPROVES HEPATIC STEATOSIS AS QUANTIFIED BY
17:30 - 17:45 CONTROLLED ATTENUATION PARAMETER (CAP)
Caroline S. Stokes, Germany
ABSTRACT REMOGLIFLOZIN ETABONATE REDUCES INSULIN
O047 RESISTANCE AND LIVER FUNCTION ENZYMES: ROLE
17:45 - 18:00 FOR TREATMENT OF NASH
Wiliam Wilkison, The United States
70 The International Liver Congress™ 2015 • ILC Programme
Parallel Session: Fatty liver disease: Clinical (Cont.) Strauss 3
ABSTRACT DISTINCT FECAL AND PLASMA BILE ACID
O044 METABOLOME OF MICROBIAL ORIGIN
17:00 - 17:15 CHARACTERIZES HUMAN NONALCOHOLIC FATTY
LIVER DISEASE (NAFLD)
SCIENTIFIC PROGRAMME Puneet Puri, The United States
ABSTRACT BIOACTIVE LIPIDS IN THE HUMAN LIVER IN ‘COMMON
O045 NAFLD’ AND ‘PNPLA3 NAFLD’
17:15 - 17:30 Panu Luukkonen, Finland
ABSTRACT SHORT-TERM VITAMIN D SUPPLEMENTATION
O046 IMPROVES HEPATIC STEATOSIS AS QUANTIFIED BY
17:30 - 17:45 CONTROLLED ATTENUATION PARAMETER (CAP)
Caroline S. Stokes, Germany
ABSTRACT REMOGLIFLOZIN ETABONATE REDUCES INSULIN
O047 RESISTANCE AND LIVER FUNCTION ENZYMES: ROLE
17:45 - 18:00 FOR TREATMENT OF NASH
Wiliam Wilkison, The United States
70 The International Liver Congress™ 2015 • ILC Programme
